D55, an Nrf2 activator that is unlikely to have DA adverse effects, appears to be a promising compound for treating neurological and psychiatric disorders, in addition to mitochondrial encephalomyopathies, due to its neuroprotective and neuroplasticity effects. Here, NFE2L2 is linked to mitochondrial encephalomyopathy.